Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Lancet 392 (10160), 21802193 (2018)
Detection of p-NF-B p65, NLRP3, caspase-1 and ASC mRNA expression in CCD-841CoN cells by RT-qPCR We established an in vitro cellular inflammation model using UC cells and administered pharmacological interventions
When Gabby lost 100 pounds, she made good on a promise to herself: She started running
Among all the side effects, severe muscle loss is the most alarming and warrants our close attention
Philadelphia, US: Wolters Kluwer Health/Lippincott Williams & Wilkins
This triple agonist design, developed by Eli Lilly under the research code LY3437943, represents a fundamentally different approach from semaglutide (which targets only GLP-1) or tirzepatide (which targets GLP-1 and GIP)
US$ 20.26
US$ 22.72
US$ 22.72
US$ 27.24
US$ 24.56
